In accordance with privacy legislation, Kedrion S.p.A., controller of the data collected through this website, hereby informs the user that this website does not use profiling cookies to send advertising messages in line with the preferences expressed when browsing the web. This website installs third party cookies. By continuing to browse, including by scrolling down and clicking on website elements, the user agrees to the company’s cookies policy.
For more information, also as regards the technical cookies used by the website and to object to the use of individual cookies, reference should be made to the complete cookies disclosure.
You are now leaving Kedrion Corporate site. Medical information including licensed uses may be different outside of the EU countries.
NO
YES
-
CORPORATE - 16-02-2018
Kedrion Biopharma runner up at the Premio Equita for the bond issued in July 2017
The prize is awarded to the companies that made the best use of the capital markets
read more -
CORPORATE - 10-01-2018
Hemophilia: Kedrion signs on to groundbreaking PARTNERS programme
Goal is to improve access to replacement therapies for coagulation disorders in Europe
read more -
CORPORATE - 31-10-2017
Kedrion and Cerus enter distribution agreement for INTERCEPT in Italy
Agreement covers complete INTERCEPT product line: platelets, plasma and red blood cells
read more -
CORPORATE - 25-08-2017
Kedrion Biopharma and Kamada Ltd Receive FDA Approval for KEDRAB®
The product is approved for post-exposure prophylaxis against rabies infection
read more
Pages
For more information please contact: pressoffice@kedrion.com
Where 